Suppr超能文献

相似文献

1
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.
Cell Rep. 2017 Jun 27;19(13):2878-2880. doi: 10.1016/j.celrep.2017.06.008.
4
Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma.
Hepatology. 2019 May;69(5):2091-2106. doi: 10.1002/hep.30493. Epub 2019 Feb 28.
5
IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
Cancer Treat Res Commun. 2021;27:100356. doi: 10.1016/j.ctarc.2021.100356. Epub 2021 Mar 24.
6
IDH mutations in liver cell plasticity and biliary cancer.
Cell Cycle. 2014;13(20):3176-82. doi: 10.4161/15384101.2014.965054.
7
Molecular classification of cholangiocarcinoma.
Curr Opin Gastroenterol. 2020 Mar;36(2):57-62. doi: 10.1097/MOG.0000000000000611.
9
Distinct histomorphological features are associated with IDH1 mutation in intrahepatic cholangiocarcinoma.
Hum Pathol. 2019 Sep;91:19-25. doi: 10.1016/j.humpath.2019.05.002. Epub 2019 May 21.
10
Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.
Nature. 2014 Sep 4;513(7516):110-4. doi: 10.1038/nature13441. Epub 2014 Jul 2.

引用本文的文献

1
Evolving roles of MET as a therapeutic target in NSCLC and beyond.
Nat Rev Clin Oncol. 2025 Jul 18. doi: 10.1038/s41571-025-01051-9.
2
Deep immune profiling of intrahepatic cholangiocarcinoma with CODEX multiplexed imaging.
Hepatol Commun. 2025 Feb 19;9(3). doi: 10.1097/HC9.0000000000000632. eCollection 2025 Mar 1.
3
Adjuvant Cytotoxic Chemotherapy may not be Associated with a Survival Advantage for Resected Intrahepatic Cholangiocarcinoma.
Ann Surg Oncol. 2025 Apr;32(4):2456-2466. doi: 10.1245/s10434-024-16799-0. Epub 2025 Jan 18.
4
Digestive cancers: mechanisms, therapeutics and management.
Signal Transduct Target Ther. 2025 Jan 15;10(1):24. doi: 10.1038/s41392-024-02097-4.
8
Unveil Intrahepatic Cholangiocarcinoma Heterogeneity through the Lens of Omics and Multi-Omics Approaches.
Cancers (Basel). 2024 Aug 20;16(16):2889. doi: 10.3390/cancers16162889.
9
10
How to incorporate new agents into precise medicine for cholangiocarcinoma?
Am J Cancer Res. 2024 May 15;14(5):2570-2583. doi: 10.62347/NFDL2398. eCollection 2024.

本文引用的文献

1
Polyclonal Secondary Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.
Cancer Discov. 2017 Mar;7(3):252-263. doi: 10.1158/2159-8290.CD-16-1000. Epub 2016 Dec 29.
2
Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise.
Oncologist. 2016 May;21(5):594-9. doi: 10.1634/theoncologist.2015-0446. Epub 2016 Mar 21.
3
Mitochondrial DNA copy number variation across human cancers.
Elife. 2016 Feb 22;5:e10769. doi: 10.7554/eLife.10769.
5
Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.
Cancer Cell. 2015 Dec 14;28(6):773-784. doi: 10.1016/j.ccell.2015.11.006.
6
SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2.
Nat Med. 2015 Dec;21(12):1491-6. doi: 10.1038/nm.3968. Epub 2015 Nov 9.
7
Functional and genetic deconstruction of the cellular origin in liver cancer.
Nat Rev Cancer. 2015 Nov;15(11):653-67. doi: 10.1038/nrc4017.
8
Loss of BAP1 function leads to EZH2-dependent transformation.
Nat Med. 2015 Nov;21(11):1344-9. doi: 10.1038/nm.3947. Epub 2015 Oct 5.
9
Genomic spectra of biliary tract cancer.
Nat Genet. 2015 Sep;47(9):1003-10. doi: 10.1038/ng.3375. Epub 2015 Aug 10.
10
Biliary Tract Cancers: Finding Better Ways to Lump and Split.
J Clin Oncol. 2015 Aug 20;33(24):2588-90. doi: 10.1200/JCO.2015.61.6953. Epub 2015 Jul 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验